10x Genomics, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation and amortization $4.3m $3.9m $7.1m $14.0m $21.1m $25.4m $35.5m $35.9m $36.2m
Amortization of right-of-use assets $0 $0 $5.0m $7.1m $7.6m $8.1m $7.8m $7.6m
Asset and lease impairment charges $9.8m $3.1m $814k
ROU assets impairment due to restructuring $0 $0 $1.3m
Operating lease liability $0 $0 ($4.8m) ($2.5m) ($6.4m) ($8.7m) ($12.5m) ($10.3m)
Right-of-use assets obtained in exchange for new operating lease liabilities $0 $0 $13.6m $21.3m $16.6m $6.5m $0 $11.4m
Net loss ($18.8m) ($112.5m) ($31.3m) ($542.7m) ($58.2m) ($166.0m) ($255.1m) ($182.6m) ($43.5m)
Stock-based compensation expense $1.7m $2.7m $13.3m $48.6m $96.0m $136.8m $166.9m $140.7m $109.1m
Fair value adjustments on contingent consideration $0 $0 $1.4m
Realized loss on marketable securities $0 $0 $1.7m $3k $0
Other $79k $2.0m $427k $523k ($1.8m)
Accounts receivable ($5.1m) ($14.7m) ($5.3m) ($17.8m) ($34.0m) ($18.9m) ($10.6m) $27.0m $41.3m
Other receivables $0 $0 ($34.9m)
Inventory ($2.0m) ($3.7m) ($6.7m) ($14.6m) ($30.1m) ($21.2m) $7.9m ($9.8m) $28.0m
Prepaid expenses and other current assets ($702k) ($2.4m) ($3.5m) ($5.3m) ($1.1m) ($4.5m) ($2.4m) ($1.9m) ($2.3m)
Other noncurrent assets $33k ($999k) ($251k) ($2.7m) $1.0m $925k ($678k) ($1.1m) $689k
Accounts payable $3.0m $2.6m $4.9m ($7.8m) $11.1m $5.9m ($6.0m) ($3.4m) ($2.1m)
Accrued compensation and other related benefits $3.5m $2.6m $5.3m $2.9m $16.3m $1.1m ($2.6m) $3.7m $7.6m
Deferred revenue $1.3m $1.7m $634k $2.0m $1.5m $3.4m $10.9m $11.2m $746k
Accrued expenses and other current liabilities $1.8m $1.7m $5.8m $25.9m ($873k) $3.3m $28.3m ($12.7m) ($5.2m)
Other noncurrent liabilities $118k $33k $547k ($3.8m) ($4.7m) ($2.9m) $1.3m $776k $1.4m
Proceeds from maturities of marketable securities $0 $0 $18.5m $82.8m $25.8m $125.2m
Proceeds from sales of marketable securities $0 $0 $49.1m $100.2m $3.9m $0
Purchase of marketable securities $0 $0 ($282.9m) $0 ($48.9m) ($123.4m)
Asset acquisition, net $0 $0 ($9.3m)
Purchases of property and equipment ($3.8m) ($6.3m) ($42.7m) ($36.7m) ($101.3m) ($131.7m) ($48.6m) ($12.4m) ($5.9m)
Purchase of intangible assets ($425k) ($25k) ($1.7m) $0 $0 ($923k) ($1.0m) $0
Payments on technology license financing arrangement $0 $0 ($5.8m) ($5.0m) ($5.4m) ($5.8m) $0 $0
Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities $250k $2.3m $4.5m $3.0m $17.0m $26.8m $3.3m $1.4m $215k
Net cash provided by (used in) operating activities ($10.7m) ($76.4m) $34.6m ($217.9m) ($21.4m) ($33.6m) ($15.2m) $6.7m $136.1m
Net cash (used in) provided by investing activities ($3.8m) ($6.7m) ($42.8m) ($38.4m) ($106.7m) ($350.9m) $133.5m ($32.6m) ($13.4m)
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases $1.8m $3.8m $23.7m $40.3m $21.2m $19.5m $10.9m $6.8m
Common stock issued for acquisition of assets $0 $0 $13.5m
Net cash provided by financing activities $20.6m $105.4m $414.6m $468.9m $35.3m $15.8m $13.7m $10.9m $6.8m
Effect of exchange rate changes on cash and cash equivalents ($14k) ($18k) ($45k) ($463k) $234k ($44k) ($33k) ($164k) $484k
Net increase (decrease) in cash and cash equivalents $6.1m $22.2m $406.4m $212.2m ($92.6m) ($368.7m) $131.9m ($15.2m) $129.9m
Cash, cash equivalents and restricted cash at beginning of year $47.9m $70.1m $476.5m $688.6m $596.1m $227.4m $359.3m $344.1m $474.0m
Cash paid for interest $658k $1.8m $2.2m $1.7m $1.2m $841k $436k $0 $0
Cash paid for taxes $6k $22k $280k $8.7m $3.9m $4.9m $5.6m $2.4m